The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Three off-the-shelf mRNA therapies join intismeran autogene.